Insider Stock Trader

Insider buy RAPP

Rapport Therapeutics, Inc. director James Healy buys $20.4M in stock

After the purchase, the filing lists 2,873,888 shares held.

James Healy purchased about $20 million of Rapport Therapeutics, Inc. (RAPP) stock on Oct 28, according to an SEC filing. The director paid an average of $21.00 for 969,480 shares.

The purchase was made in the open market, not through an award, an option exercise or a plan. Other Rapport Therapeutics, Inc. insiders have also bought: Six insiders made open-market purchases within 14 days, a pattern known as a cluster buy.

With this purchase the insider holds 2,873,888 shares, 51% more than before. The trade was reported within two business days, as Section 16 requires.

Figures come from the Form 4 filed with the SEC; the table lists the open-market rows this article covers.

The purchase
CompanyRapport Therapeutics, Inc. (RAPP)
InsiderJames Healy
RoleDirector
TransactionOpen-market purchase (code P)
Shares969,480
Average price$21.00
Value$20,359,080
Trade dateOct 28, 2026
Filed with the SECOct 30, 2026, 7:32 PM ET
Shares held after2,873,888
OwnershipIndirect
Rule 10b5-1 planNot marked in the filing

See the full details of this insider trade

View the Form 4 on SEC.gov

See where several insiders traded together · Browse the insider trading newsroom

Source: SEC Form 4. Information only, not investment advice. Not affiliated with or endorsed by the U.S. Securities and Exchange Commission.